In vivo anticancer and histopathology studies of Schiff bases on Ehrlich ascitic carcinoma cells 1st Cancer Update

AbstractThree Schiff bases in two different concentrations were evaluated for their anti-tumor activity against Ehrlich ascites carcinoma (EAC) bearing Swiss albino mice. The in vivo anti-tumor potency of Schiff bases was assessed by measuring the increase in mean survival time of the drug treated over untreated control mice and treated standard (cisplatin) mice. Their toxicity was assessed in vivo in normal, standard, and EAC-bearing mice by measuring the drug-induced changes in biochemical as well as hematological parameters. The histopathology studies to assess the toxicity of these compounds on vital organs also have been studied. Among the three Schiff bases studied, 4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methylene}amino)-5-[(2-methylphenoxy)methyl]-1,2,4-triazole-3-thiol (SB-3) at an optimal dose of 100mg/kg body weight was found to enhance the mean survival time of infected mice. Deviated hematological parameters and mean survival time in tumor bearing mice were found to be significantly restored towards normal after treatment with SB-3 100mg/kg body weight of mice. The ALP and SGOT values were found to approach the normal range. A:G ratios also did not deviate from normal on treatment with SB-3. The histopathology studies revealed only mild hepatotoxicity and nephrotoxicity when compared to the normal and standard. The splenic cellularity also did not show much variation from normal. SB-3 at a prime dose of 100mg has shown promising anticancer activity in vivo against EAC when compared to standard drug with minimum toxic effects